Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel
NYSE:EBS

Emergent Biosolutions Q3 2026 Earnings Date & Estimates

Emergent Biosolutions logo
$6.94 +0.03 (+0.43%)
As of 11:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Emergent Biosolutions is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for October 28, 2026 at 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Emergent Biosolutions in Q3 2026

Emergent Biosolutions is expected to post earnings of -$0.37 per share on revenue of $123.22 million. In the same quarter a year earlier Emergent Biosolutions reported $1.06 per share on revenue of $231.10 million. Emergent Biosolutions last reported on August 5, 2026, posting $0.60 per share and beating the -$0.0850 consensus estimate. Emergent Biosolutions has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.37
Expected Revenue
$123.22 million
Prior-Year EPS
$1.06
Prior-Year Revenue
$231.10 million
Expected EPS Growth
-134.9%
Expected Revenue Growth
-46.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.60 (Beat by +$0.6850)
Last Quarter Revenue
$234.30 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Emergent Biosolutions Q3 2026 Earnings FAQ

Emergent Biosolutions (NYSE:EBS) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Emergent Biosolutions' Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Emergent Biosolutions to post earnings of -$0.37 per share for Q3 2026.

The consensus revenue estimate for Emergent Biosolutions is $123.22 million for Q3 2026.

Emergent Biosolutions Earnings Headlines

Comparing Sutro Biopharma (NASDAQ:STRO) & Emergent Biosolutions (NYSE:EBS)
October 11 at 6:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107620
Insider Selling: Emergent Biosolutions (NYSE:EBS) SVP Sells $19,590.00 in Stock
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31087499
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.tc pixel
October 14 at 1:00 AM  |  Weiss Ratings (Ad)
Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Average Target Price of $10.00
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085907
Contrasting Immatics (NASDAQ:IMTX) and Emergent Biosolutions (NYSE:EBS)
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084295
Caribou Biosciences (NASDAQ:CRBU) versus Emergent Biosolutions (NYSE:EBS) Head to Head Contrast
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082601
See More Emergent Biosolutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Emergent Biosolutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Emergent Biosolutions and other key companies, straight to your email.

About Emergent Biosolutions

Emergent Biosolutions (NYSE:EBS) (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin. The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology organizations.

Founded in 1998, Emergent is headquartered in Gaithersburg, Maryland. Its operations and customer relationships have included the United States and international markets, with a significant portion of its business tied to government preparedness programs. Joseph C. Papa serves as the company’s chief executive officer.

View Emergent Biosolutions Profile
Earnings Tools